ABIONYX Pharma SA (ABNX.PA)
EUR 1.24
(2.15%)
EUR 1.24
(2.15%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 618 Thousand EUR | 79.4% |
| 2022 | 636 Thousand EUR | 145.56% |
| 2021 | 259 Thousand EUR | 423.75% |
| 2020 | -80 Thousand EUR | -11.11% |
| 2019 | -72 Thousand EUR | -141.38% |
| 2018 | 174 Thousand EUR | 504.65% |
| 2017 | -43 Thousand EUR | 18.87% |
| 2016 | -53 Thousand EUR | 3.64% |
| 2015 | -55 Thousand EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 275 Thousand EUR | 0.0% |
| 2023 Q4 | 314.5 Thousand EUR | 0.0% |
| 2023 FY | 1.14 Million EUR | 79.4% |
| 2023 Q1 | -5500.00 EUR | -101.23% |
| 2023 Q2 | -30 Thousand EUR | -445.45% |
| 2023 Q3 | 314.5 Thousand EUR | 1148.33% |
| 2022 Q3 | 272 Thousand EUR | 403.71% |
| 2022 Q2 | 54 Thousand EUR | 17.39% |
| 2022 Q1 | 46 Thousand EUR | -71.78% |
| 2022 Q4 | 448 Thousand EUR | 64.71% |
| 2022 FY | 636 Thousand EUR | 145.56% |
| 2021 Q2 | -11 Thousand EUR | -181.48% |
| 2021 Q3 | 116 Thousand EUR | 1154.55% |
| 2021 Q4 | 163 Thousand EUR | 40.52% |
| 2021 FY | 259 Thousand EUR | 423.75% |
| 2021 Q1 | 13.5 Thousand EUR | 132.14% |
| 2020 FY | -80 Thousand EUR | -11.11% |
| 2020 Q4 | -42 Thousand EUR | 0.0% |
| 2020 Q3 | - EUR | 100.0% |
| 2020 Q2 | -38 Thousand EUR | 0.0% |
| 2020 Q1 | - EUR | 100.0% |
| 2019 FY | -72 Thousand EUR | -141.38% |
| 2019 Q1 | - EUR | -100.0% |
| 2019 Q4 | -36 Thousand EUR | 0.0% |
| 2019 Q2 | -36 Thousand EUR | 0.0% |
| 2019 Q3 | - EUR | 100.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q1 | - EUR | 0.0% |
| 2018 FY | 174 Thousand EUR | 504.65% |
| 2018 Q4 | 87 Thousand EUR | 0.0% |
| 2018 Q3 | 87 Thousand EUR | 0.0% |
| 2017 FY | -43 Thousand EUR | 18.87% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q4 | - EUR | 0.0% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 Q3 | - EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 FY | -53 Thousand EUR | 3.64% |
| 2015 FY | -55 Thousand EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIVAX Société Anonyme | 3.91 Million EUR | 84.211% |
| Adocia SA | 1.38 Million EUR | 55.379% |
| Aelis Farma SA | 12.35 Million EUR | 94.999% |
| Biophytis S.A. | -803 Thousand EUR | 176.961% |
| Advicenne S.A. | 1.42 Million EUR | 56.662% |
| genOway Société anonyme | 20.1 Million EUR | 96.925% |
| IntegraGen SA | 5.01 Million EUR | 87.685% |
| Medesis Pharma S.A. | -2.66 Million EUR | 123.192% |
| Neovacs S.A. | 29.31 Thousand EUR | -2008.208% |
| NFL Biosciences SA | -56.06 Thousand EUR | 1202.312% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 71.295% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 143.543% |
| Sensorion SA | 3.78 Million EUR | 83.685% |
| Theranexus Société Anonyme | -4.63 Million EUR | 113.323% |
| TME Pharma N.V. | -127 Thousand EUR | 586.614% |
| Valbiotis SA | 2.66 Million EUR | 76.837% |
| TheraVet SA | -530.79 Thousand EUR | 216.429% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 51.223% |
| DBV Technologies S.A. | 4.15 Million EUR | 85.143% |
| Genfit S.A. | 28.22 Million EUR | 97.81% |
| GeNeuro SA | -293.8 Thousand EUR | 310.347% |
| Innate Pharma S.A. | -4.12 Million EUR | 114.996% |
| Inventiva S.A. | 17.5 Million EUR | 96.469% |
| MaaT Pharma SA | 1.65 Million EUR | 62.659% |
| MedinCell S.A. | 9.28 Million EUR | 93.346% |
| Nanobiotix S.A. | 36.2 Million EUR | 98.293% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 72.25% |
| Poxel S.A. | 1000.00 EUR | -61700.0% |
| GenSight Biologics S.A. | 3 Million EUR | 79.4% |
| Transgene SA | -28.4 Million EUR | 102.176% |
| Valneva SE | 52.83 Million EUR | 98.83% |